Australia's most trusted
source of pharma news
Posted 18 February 2025 PM
The Snow Medical Research Foundation has committed $50 million to potentially disrupt the glaucoma market by developing a treatment that targets age-related vulnerabilities of the optic nerve.
The funding will be provided over the next decade and used to launch the Snow Vision Accelerator in partnership with the University of Sydney, which will be led by world-renowned ophthalmologist Professor Jonathan Crowston. It marks the largest single philanthropic investment in vision science in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.